Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma
- 3 November 2014
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 56 (5) , 1335-1341
Abstract
After autologous stem cell transplant (AuSCT), patients with multiple myeloma (MM) may receive lenalidomide maintenance therapy. This longitudinal study examined patient-reported symptom burden during the 3–9 months post-AuSCT and its association with maintenance therapy and circulating inflammatory markers. Fifty-one patients with MM rated symptom severity weekly using the MD Anderson Symptom Inventory MM module. When possible, blood for inflammatory marker assay was drawn at enrollment. Trajectory analysis identified clusters of patients who consistently reported higher or lower symptom severity. Although disease was relatively stable 3–9 months post-AuSCT, patients were not symptom-free: 35% were in the high-symptom group. Fatigue, pain, numbness/tingling, bone aches and muscle weakness were the most severe symptoms. Controlled for clinical variables, elevated baseline tumor necrosis factor-α (TNF-α) predicted high-symptom group membership (p = 0.014). Maintenance therapy and tumor response were not related to high symptom burden. Associations between inflammation and symptom burden in this exploratory study warrant further confirmatory study.Keywords
This publication has 29 references indexed in Scilit:
- Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapyOncoImmunology, 2013
- Validation of the M. D. Anderson Symptom Inventory multiple myeloma moduleJournal of Hematology & Oncology, 2013
- Management of treatment-emergent peripheral neuropathy in multiple myelomaLeukemia, 2011
- Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapyBrain, Behavior, and Immunity, 2010
- Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple MyelomaJournal of Clinical Oncology, 2009
- Serum interleukin‐6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantationCancer, 2008
- An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myelomaLeukemia & Lymphoma, 2007
- Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myelomaBlood, 2002
- Circulating IL‐6‐type cytokines and sIL‐6R in patients with multiple myelomaBritish Journal of Haematology, 1999
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994